4//SEC Filing
Robinson Chandler 4
Accession 0001437749-25-021994
CIK 0001645469other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:25 PM ET
Size
10.8 KB
Accession
0001437749-25-021994
Insider Transaction Report
Form 4
Robinson Chandler
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-06-30−13,344→ 81,325 total→ Common Stock (13,344 underlying) - Exercise/Conversion
Common Stock
2025-06-30+13,344→ 79,337 total - Tax Payment
Common Stock
2025-06-30$35.78/sh−5,865$209,850→ 73,472 total
Holdings
- 822,255(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]Represents shares acquired on vesting and settlement of restricted stock units.
- [F2]Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- [F3]As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 822,255 shares. Dr. Robinson disclaims beneficial ownership of the 822,255 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
- [F4]On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F5]On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F6]On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Documents
Issuer
Monopar Therapeutics
CIK 0001645469
Entity typeother
Related Parties
1- filerCIK 0001727334
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:25 PM ET
- Size
- 10.8 KB